(Q37542362)

20 August 2017

1 reference

title

Central nervous system is a sanctuary site for chronic myelogenous leukaemia treated with imatinib mesylate (English)

1 reference

20 August 2017

1 reference

0 references

1 reference

Y Isobe

1

1 reference

20 August 2017

K Sugimoto

2

1 reference

20 August 2017

A Masuda

3

1 reference

20 August 2017

Y Hamano

4

1 reference

20 August 2017

K Oshimi

5

1 reference

20 August 2017

publication date

1 June 2009

1 reference

Internal Medicine Journal

20 August 2017

published in

1 reference

20 August 2017

volume

39

1 reference

20 August 2017

issue

6

1 reference

20 August 2017

page(s)

408-411

1 reference

STI-571 in chronic myelogenous leukaemia

20 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1445-5994.2009.01947.X

Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1445-5994.2009.01947.X

Low concentrations of STI571 in the cerebrospinal fluid: a case report

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1445-5994.2009.01947.X

Isolated central nervous system relapse in lymphoid blast crisis chronic myeloid leukemia and acute lymphoblastic leukemia in patients on imatinib therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1445-5994.2009.01947.X

Isolated central nervous system blast crisis in chronic myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1445-5994.2009.01947.X

Extramedullary blast crisis derived from 2 different clones in the central nervous system and neck during complete cytogenetic remission of chronic myelogenous leukemia treated with imatinib mesylate

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1445-5994.2009.01947.X

Extramedullary blast crises in CML patients in complete hematological remission treated with imatinib mesylate

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1445-5994.2009.01947.X

Pharmacokinetics and pharmacodynamics of imatinib in a phase I trial with chronic myeloid leukemia patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1445-5994.2009.01947.X

Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1445-5994.2009.01947.X

The CNS is a sanctuary for leukemic cells in mice receiving imatinib mesylate for Bcr/Abl-induced leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1445-5994.2009.01947.X

Distribution of STI-571 to the brain is limited by P-glycoprotein-mediated efflux

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1445-5994.2009.01947.X

10.1111/J.1445-5994.2009.01947.X

21 January 2018

Identifiers

DOI

1 reference

20 August 2017

1 reference